Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 54,948 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hemophilia A
Interventions: Kogenate (BAY 14-2222); Drug
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 60 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 2
States / cities: Detroit, Michigan • Las Vegas, Nevada

Conditions: Hodgkin Disease, Non-Hodgkins Lymphoma
Interventions: Infusion of EBV Specific Cytotoxic T-Lymphocytes; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2006
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
Interventions: CARv3-TEAM-E T cells; Drug
Lead sponsor: Marcela V. Maus, M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neurofibroma, Plexiform, Neurofibromatosis Type I
Interventions: tipifarnib, placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 25 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more

Conditions: Knee Osteoarthritis
Interventions: Physical Therapy; Other
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: Not listed
Enrollment: 18 participants
Timeline: 2018
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Non-segmental Vitiligo
Interventions: Roflumilast topical 0.3% foam; Drug
Lead sponsor: Derm Texas, PLLC; Network
Eligibility: 2 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Spiritual Care, Advanced Cancer
Interventions: Peace Intervention, Usual Care; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndrome RAEB-I or RAEB-II, Refractory Acute Myeloid Leukemia, Refractory CML Myeloid Blast Crisis
Interventions: GM-CSF secreting leukemia vaccine; Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia
Interventions: NSA-789 at 2 different doses; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cancer Patients, Survivor Patients, Cancer Pain
Interventions: Topical herbal plaster; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Coronary Heart Disease
Interventions: Placebo, dalcetrapib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 6 more

Conditions: Low Anterior Resection Syndrome, Rectal Carcinoma
Interventions: Dietary Fiber, Enema Administration, Loperamide Hydrochloride, Physical Therapy, Questionnaire Administration, X-Ray Imaging; Dietary Supplement · Procedure · Drug + 1 more
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Tetraplegia
Interventions: Neural Prosthetic System; Device
Lead sponsor: Richard A. Andersen, PhD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 3
States / cities: Downey, California • Los Angeles, California • Pasadena, California

Conditions: Pain, Postoperative, Medication Adherence, Opioid Use, Knowledge, Attitudes, Practice, Risk Reduction Behavior
Interventions: Educational Intervention, Nudge; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 99 Years
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Inflammatory Breast Carcinoma
Interventions: 89Zr-bevacizumab, FDG-PET/CT, MRI scan, Tumor biopsies; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 21 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Vitiligo
Interventions: Narrowband UVB; Device
Lead sponsor: Mary Sullivan-Whalen; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma
Interventions: Pembrolizumab; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, End Stage Liver DIsease, Cirrhosis, Liver
Interventions: Siplizumab; Drug
Lead sponsor: Elizabeth C. Verna; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Physical Therapy
Interventions: FORCE therapeutics (physical therapy), Traditional Outpatient Physical Therapy; Procedure
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: SLE
Interventions: Envudeucitinib, Placebo; Drug
Lead sponsor: Alumis Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 48
States / cities: Anniston, Alabama • La Jolla, California • Los Alamitos, California + 38 more

Conditions: Rheumatoid Arthritis
Interventions: abatacept; Biological
Lead sponsor: Arthritis & Rheumatic Disease Specialties Research; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Coronary Artery Disease
Interventions: PB127 for Injectable Suspension; Drug
Lead sponsor: Point Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 40
States / cities: Tucson, Arizona • Burlingame, California • Long Beach, California + 33 more

Conditions: Mantle Cell Lymphoma, B Cell Lymphoma
Interventions: Sonrotoclax, Zanubrutinib, Placebo; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more

Search by objective public record fields.

Influenza Vaccine in Lung Transplant Patients

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease

CARv3-TEAM-E T Cells in Glioblastoma

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Influence of Manual Physical Therapy on Habitual Activity in Knee Osteoarthritis

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in Patients With Advanced Cancer: a Pilot Clinical Trial

GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies

Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients

A Study Testing Topical Pain-Relieving Herbal Plasters in People Who Are Using Opioids for Their Pain

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients

Providing Brain Control of Extracorporeal Devices to Patients With Quadriplegia

Evaluation of an Interactive Opioid Risk Education Program (STOMP) for Parents

Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

Narrowband UVB Treatment in Patients With Vitiligo

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

A Study of SIPLIZUMAB in AILD and LT Patients

Traditional PT v Internet Based PT After Total Knee Arthroscopy

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)